机译:Yttrium-90 ibritumomab Tiuxetan(Zevalin)随后是梁(Z-梁)调节方案和自体干细胞移植(ASCT)复发或难治性高风险B细胞非霍奇金淋巴瘤(NHL):一种机构意大利经验
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Citta Salute &
Sci Hematol Dept Corso Bramante 88 I-10126 Turin Italy;
Autologous stem cell transplantation; Aggressive refractory NHL; Zevalin;
机译:Yttrium-90 ibritumomab Tiuxetan(Zevalin)随后是梁(Z-梁)调节方案和自体干细胞移植(ASCT)复发或难治性高风险B细胞非霍奇金淋巴瘤(NHL):一种机构意大利经验
机译:钇90 ibritumomab tiuxetan BEAM调理后的自体干细胞移植治疗难治性非霍奇金弥漫性大B细胞淋巴瘤:一项前瞻性,多中心,II期临床试验的结果|血液学
机译:一项随机研究比较了yttrium-90 ibritumomab tiuxetan(Zevalin)和大剂量BEAM化疗与单纯BEAM作为自发干细胞移植治疗恶性淋巴瘤患者的治疗方案
机译:高剂量素母蛋白和自体干细胞移植(HDM / SCT)用于治疗Al淀粉样症:十年单一制度经验
机译:钇90 ibritumomab tiuxetan BEAM调理后的自体干细胞移植治疗难治性非霍奇金弥漫性大B细胞淋巴瘤:一项前瞻性多中心II期临床试验的结果
机译:充满希望的城市,拥有结合标准剂量和递增剂量的90YTTRIUM ibritumomab tiuxetan(90Y-Zevalin®)放射免疫疗法(RIT)进行B细胞非霍奇金淋巴瘤(NHL)患者自体干细胞移植(ASCT)的新型移植方案:有针对性的强化治疗,而不会增加毒性并消除全身辐射(TBI)